Clinical evaluation of deprenyl (selegiline) in the treatment of Parkinson's disease
| Autor: | M. Tárczy, E. Csanda |
|---|---|
| Rok vydání: | 1983 |
| Předmět: |
Male
Levodopa Parkinson's disease Benserazide Disability Evaluation Pharmacotherapy Phenethylamines Selegiline medicine Humans Aged Dose-Response Relationship Drug business.industry Parkinson Disease General Medicine Middle Aged medicine.disease nervous system diseases Drug Combinations Neurology Anesthesia Drug Evaluation Drug Therapy Combination Neurology (clinical) business Clinical evaluation medicine.drug |
| Zdroj: | Acta Neurologica Scandinavica. 68:117-122 |
| ISSN: | 1600-0404 0001-6314 |
| DOI: | 10.1111/j.1600-0404.1983.tb01525.x |
| Popis: | The experiences of a seven-year study on deprenyl in the treatment of Parkinson's disease are summarized. It was found that the main advantage of deprenyl was that it permitted the reduction of the dose of levodopa in optimally treated patients. In the initial stage of Parkinson's disease deprenyl is only partially sufficient as monotherapy. Deprenyl can administered successfully for correcting the "wearing off" effect. |
| Databáze: | OpenAIRE |
| Externí odkaz: |
|